

PODOLSKA, Alicja, WOŹNIACKA, Agnieszka, BOBA, Barbara, CHOJNACKA, Barbara, WĄTOR, Julia, KRZESZOWIAK, Jerzy, OŹGA, Aleksandra, KOLANO, Patrycja, BRYKSY, Sylwia and PULANECKI, Tomasz. The Impact of Lifestyle on the Course of Hashimoto's Disease: The Role of Diet, Physical Activity, and Stress - A Literature Review. *Quality in Sport*. 2025;43:61288. eISSN 2450-3118.

<https://doi.org/10.12775/QS.2025.43.61288>

<https://apcz.umk.pl/QS/article/view/61288>

The journal has been awarded 20 points in the parametric evaluation by the Ministry of Higher Education and Science of Poland. This is according to the Annex to the announcement of the Minister of Higher Education and Science dated 05.01.2024, No. 32553. The journal has a Unique Identifier: 201398. Scientific disciplines assigned: Economics and Finance (Field of Social Sciences); Management and Quality Sciences (Field of Social Sciences).

Punkty Ministerialne z 2019 - aktualny rok 20 punktów. Załącznik do komunikatu Ministra Szkolnictwa Wyższego i Nauki z dnia 05.01.2024 Lp. 32553. Posiada Unikatowy Identyfikator Czasopisma: 201398. Przypisane dyscypliny naukowe: Ekonomia i finanse (Dziedzina nauk społecznych); Nauki o zarządzaniu i jakości (Dziedzina nauk społecznych). © The Authors 2025.

This article is published with open access under the License Open Journal Systems of Nicolaus Copernicus University in Torun, Poland. Open Access: This article is distributed under the terms of the Creative Commons Attribution Noncommercial License, which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited. This is an open access article licensed under the terms of the Creative Commons Attribution Non-commercial Share Alike License (<http://creativecommons.org/licenses/by-nc-sa/4.0/>), which permits unrestricted, non-commercial use, distribution, and reproduction in any medium, provided the work is properly cited.

The authors declare that there is no conflict of interest regarding the publication of this paper.

Received: 20.05.2025. Revised: 25.06.2025. Accepted: 30.06.2025. Published: 04.07.2025.

The Impact of Lifestyle on the Course of Hashimoto's Disease: The Role of Diet, Physical Activity, and Stress - A Literature Review

PODOLSKA Alicja, WOŹNIACKA, Agnieszka, BOBA, Barbara, CHOJNACKA, Barbara, WĄTOR, Julia, KRZESZOWIAK Jakub, OŹGA Aleksandra, KOLANO, Patrycja, BRYKSY, Sylwia, PULANECKI, Tomasz

1. Alicja Podolska (AP)
The University Hospital in Krakow, Jakubowskiego 2 Street, 30-688 Krakow, Poland
<https://orcid.org/0009-0002-7690-1406>
apodolska1@gmail.com
2. Agnieszka Woźniacka (AW)
Hospital of Santa Anne in Miechów, Szpitalna 3 Street, 32-200 Miechów, Poland
<https://orcid.org/0009-0009-7840-499X>
agnieszka.wozniacka@proton.me
3. Barbara Boba (BB)
5 th Military Clinical Hospital with Policlinic (SPZOZ) in Cracow, Wrocławska Street 1-3, 30-901 Cracow, Poland
<https://orcid.org/0009-0004-7939-8783>
basia.b44@gmail.com
4. Barbara Chojnacka (BC)
5 th Military Clinical Hospital with Policlinic (SPZOZ) in Cracow, Wrocławska Street 1-3, 30-901 Cracow, Poland
<https://orcid.org/0009-0009-2978-9993>
basia.chojnacka34@gmail.com

5. Julia Wator (JW)
Silesian Medical University in Katowice, Poniatowskiego 15 Street, 40-055 Katowice, Poland
<https://orcid.org/0009-0003-0120-5198>
julia.katarzyna.wator@gmail.com
6. Jerzy Krzeszowiak (JK)
Jagiellonian University Medical College in Cracow, Santa Anne 12 Street, 31-008 Cracow, Poland
<https://orcid.org/0000-0002-8831-6565>
jerzykrzeszowiak2206@gmail.com
7. Aleksandra Ożga (AO)
Warsaw South Hospital, Rotmistrza Witolda Pileckiego Street 99, 02-781 Warsaw, Poland
<https://orcid.org/0009-0002-1279-543X>
ola.ozgao@gmail.com
8. Patrycja Kolano (PK)
Medical Center in Łańcut, Ignacego Paderewskiego 5 Street, 37-100 Łańcut, Poland
<https://orcid.org/0009-0009-1706-5752>
patrycja.kolano97@gmail.com
9. Sylwia Bryksy (SB)
5 th Military Clinical Hospital with Policlinic (SPZOZ) in Cracow, Wrocławska Street 1-3, 30-901 Cracow, Poland
<https://orcid.org/0009-0007-7877-1541>
bryksy.syl@gmail.com
10. Tomasz Pulanecki (TP)
The University Hospital in Cracow, Jakubowskiego 2 Street, 30-688 Cracow, Poland
<https://orcid.org/0009-0005-5662-2268>
tomaszpulanecki@gmail.com

Abstract

Introduction and purpose of the work: Hashimoto's thyroiditis (HT), also called chronic autoimmune lymphocytic thyroiditis, is a major cause of hypothyroidism in iodine-sufficient areas. It affects women more often and may co-occur with other autoimmune diseases. HT involves T-cell mediated damage to thyroid cells and the presence of anti-TPO and anti-Tg antibodies. While levothyroxine restores hormone levels, many patients still report fatigue, mood issues, and cognitive problems. This review examines how lifestyle factors—diet, exercise, and stress—affect the course of HT and patient outcomes.

State of knowledge: Environmental and behavioral factors are increasingly recognized in autoimmune disease progression. Diets high in processed foods and low in micronutrients may promote inflammation and gut imbalance, worsening autoimmunity. Sedentary behavior and chronic stress also impair immune function. On the other hand, anti-inflammatory diets,

physical activity, and stress management may support immune balance and complement standard HT treatment.

Materials and methods: A literature review was conducted in PubMed for studies up to 2025, including reviews, original articles, and observational studies in English focused on lifestyle factors in HT.

Summary: Lifestyle changes—such as anti-inflammatory diets (e.g., Mediterranean, AIP), regular physical activity, and stress reduction—can improve symptoms and modulate disease markers in HT. These findings support integrating holistic strategies into patient care.

Keywords: lifestyle medicine, physical activity, Hashimoto's thyroiditis, autoimmunity, Mediterranean diet, chronic stress, immune modulation

1. Introduction

Hashimoto's thyroiditis (HT) is the most common autoimmune endocrine disease and the main cause of hypothyroidism in iodine-sufficient areas [1]. The first mention of autoimmune thyroiditis dates back to 1912, when Japanese doctor Hakaru Hashimoto described four cases of patients with thyroid lesions in the form of goiter, clinically characterized by a diffuse enlargement of the thyroid gland [2]. During palpation, an enlarged thyroid gland is usually painless and has a hard and smooth surface. However, as the condition develops, the thyroid gland becomes smaller and nodules may begin to appear [3].

HT development leads to scarring and destruction of the thyroid gland and is manifested by a decrease of plasma free triiodothyronine (T3) and thyroxine (T4), elevated plasma levels of thyroid-stimulating hormone (TSH) [4]. It is characterized by high levels of thyroid antibodies. Specifically, it is marked by elevated levels of anti-TPO (thyroid peroxidase) and anti-Tg (thyroglobulin) antibodies in serum, and it is influenced by many factors. [5-6].

Other diagnostic methods in approaching HT include ultrasonography (USG) of the thyroid gland and fine needle aspiration (FNA) [1,7]. The most commonly observed changes in the USG are enlargement, hypoechogenicity of the thyroid parenchyma, and hypervascularity, although it depends on the phase of HT [7-9]. Single or multiple nodules in the parenchyma of the thyroid may be present in the nodular type of HT [7].

In adults with Hashimoto's thyroiditis (HT), clinical presentation predominantly involves cutaneous manifestations, including marked xerosis and scaling, most pronounced on the palms, soles, and extensor surfaces. Hair abnormalities are also frequently observed, with diminished growth velocity and structural impairment resulting in hair that is dry, brittle, and lacking luster. Hypothyroid states secondary to HT can induce an increase in peripheral vascular

resistance by 50%–60%, accompanied by a reduction in cardiac output by approximately 30%–50%. A heritable genetic predisposition is considered a major determinant underlying the elevated incidence and relative risk of coexisting autoimmune diseases among HT patients and their first-degree relatives [10-11]. In addition, a significantly higher incidence of depressive and anxiety disorders has been reported among patients with autoimmune thyroiditis (AIT) [12]. Furthermore, individuals with AIT appear to be at increased risk not only for thyroid carcinoma but also for breast, pulmonary, gastrointestinal, genitourinary, and hematologic malignancies, as well as prolactinoma [13].

According to the American Thyroid Association (for 2023) [5], the diagnostic criteria for autoimmune thyroiditis include:

1. symptoms of hypothyroidism combined with elevated Thyroid Stimulating Hormone (TSH) levels, with or without low thyroid hormone levels; ^{[[1]]}_{SEP}
2. enlargement of the thyroid gland (goiter); ^{[[1]]}_{SEP}
3. elevated thyroid antibody levels.

2. Epidemiology

The incidence of Hashimoto's thyroiditis is estimated at 0.3–1.5 cases per 1,000 individuals, with a pronounced female predominance reflected by a female-to-male ratio of approximately 7–10:1 [10,14]. Ethnic variability has also been observed, with a higher prevalence reported among individuals of Caucasian ancestry compared to African American or Asian populations, and a notably low incidence among Pacific Islanders [15]. Advancing age constitutes a significant risk factor for the development of Hashimoto's thyroiditis [10], particularly in individuals with concomitant autoimmune disorders, including myasthenia gravis [16], systemic sclerosis [17], connective tissue diseases [18], Sjögren's syndrome [19-20], pernicious anemia [19-20], autoimmune hepatitis, and celiac disease [18-20]. The frequent coexistence of multiple autoimmune diseases, a phenomenon termed polyautoimmunity, is believed to arise from intricate interactions among immune dysregulation, hormonal influences, genetic predisposition, and environmental exposures [21]. Moreover, among the female population, an increased prevalence of Hashimoto's thyroiditis has been identified in patients diagnosed with polycystic ovary syndrome (PCOS) [22-23]. The incidence of autoimmune thyroiditis (AIT) exhibits an age-dependent rise, with peak occurrence observed between 45

and 65 years, although cases are also documented in pediatric cohorts [3,24]. Notably, in the pediatric population, the presence of chromosomal aberrations such as Down syndrome, Turner syndrome, and Klinefelter syndrome has been associated with a heightened risk of developing AIT [25].

3.Pathophysiology

Hashimoto's thyroiditis (HT) is an autoimmune disease influenced by both genetic and environmental factors. Genetic predisposition involves polymorphisms in HLA, CTLA-4, PTPN22, and genes regulating T and B cell tolerance, as well as X chromosome inactivation mechanisms [20,26-27]. Additional susceptibility is associated with polymorphisms in autoantigens, cytokines (e.g., IL2R), estrogen receptors, adhesion molecules (CD14, CD40), and genes involved in apoptosis and selenoprotein expression [20,28-29] [30-31]. Epigenetic mechanisms such as methylation, histone modification, and non-coding RNA interference further modulate disease risk. Environmental triggers include infections, smoking, fetal-maternal microchimerism, and chemical exposures like phthalates and flame retardants [32-33]. Interestingly, low environmental exposure (e.g., overly hygienic conditions) also correlates with higher rates of autoimmune diseases, including HT [34]. Gut microbiota composition is increasingly linked to HT, with a reduced presence of beneficial genera (e.g., *Bifidobacterium*, *Lactobacillus*) and an increase in pathogenic bacteria such as *Bacteroides fragilis* observed in HT patients [35].

Diet also plays a significant role in the course of HT. Excessive iodine intake may increase disease incidence up to fourfold by enhancing thyroglobulin (Tg) immunogenicity in genetically susceptible individuals [36-37]. Although excessive supplementation is not recommended in HT, iodine intake of up to 250 µg/day is advised for pregnant and breastfeeding women [38]. Low selenium intake might contribute to disease activation; however, while supplementation reduces anti-TPO levels, it does not alter disease progression [39-40].

A gluten-restricted diet has been suggested as a potential modulator in HT, especially in patients with coexisting celiac disease. Studies show reduced thyroid volume or decreased anti-TPO levels in gluten-free individuals, though the clinical relevance of antibody reduction remains unclear [41-42].

Mechanistically, HT is characterized by T-cell-mediated destruction of thyroid tissue, with histopathological features including lymphoplasmacytic infiltration, fibrosis, and follicular atrophy [43]. Variants of HT include fibrotic, atrophic, Riedel's thyroiditis, and IgG4-

related forms [44-46]. Single-cell RNA sequencing has revealed the key role of thyroid stromal cell subtypes in recruiting immune cells that intensify thyroid destruction and antigen exposure (TPO, Tg), further amplifying autoimmune responses [47]. Notably, elevated anti-TPO and anti-Tg antibodies are more common (15–25%) than clinical hypothyroidism, especially in iodine-sufficient populations, in women, and in older adults [48].

4. Results

4.1. Impact of diet on the course of Hashimoto's Disease

Dietary interventions play a pivotal role in modulating immune function and inflammatory status in HT. The Western diet (WD), marked by high intake of saturated fats, refined sugars, animal proteins, and ultra-processed foods, alongside low consumption of fiber, antioxidants, and micronutrients, has been associated with an increased risk of autoimmune diseases, including Hashimoto's thyroiditis [49-55]. These dietary habits promote chronic low-grade inflammation ("metainflammation"), oxidative stress, and immune dysregulation through increased pro-inflammatory cytokines (e.g., IL-6, IL-17, TNF- α) and imbalances in regulatory T cell function [56-61]. Furthermore, WD negatively impacts the gut microbiota and intestinal barrier, leading to dysbiosis and enhanced intestinal permeability. This "leaky gut" state allows microbial and dietary antigens to enter systemic circulation, triggering autoimmune responses in genetically predisposed individuals [62-67]. Reduced intake of antioxidants and excessive consumption of red and processed meats further aggravate oxidative stress, a key factor in thyroid autoimmunity [68]. Current evidence supports the view that WD contributes to the initiation and exacerbation of autoimmune thyroid disorders by promoting systemic inflammation, oxidative damage, and gut-derived immune activation.

In contrast to the pro-inflammatory nature of the Western diet, the Mediterranean diet (MD) represents a well-established model of anti-inflammatory, nutrient-dense nutrition. Originating from traditional eating patterns of populations in the Mediterranean basin, the MD is characterized by a high intake of plant-based foods (e.g., vegetables, fruits, legumes, nuts, whole grains), moderate consumption of fish, dairy, and red wine, and olive oil as the primary lipid source [69-70]. Rich in monounsaturated fatty acids, omega-3 polyunsaturated fatty acids (PUFAs), fiber, and essential micronutrients (e.g., selenium, iodine, zinc, vitamins E, B, C, and β -carotene), the MD supports oxidative balance, reduces systemic inflammation, and positively modulates the gut microbiome and immune function [71-73]. Importantly, its health effects are

attributed not to isolated nutrients, but to the synergistic action of multiple bioactive compounds consumed as part of a whole-diet approach [74-75]. Beyond its cardioprotective effects demonstrated in the seminal *Seven Country Study*, the MD has been associated with reduced incidence of metabolic syndrome and emerging protection against autoimmune diseases [76-84]. Recent studies highlight its immunomodulatory and antioxidant properties, making it a rational dietary model for individuals with autoimmune thyroid disorders, including Hashimoto's thyroiditis [85-86]. Moreover, the MD is recognized by UNESCO as part of the Intangible Cultural Heritage of Humanity, not only for its nutritional composition but also for its broader lifestyle and cultural dimensions, emphasizing food quality, sustainability, and shared eating practices [87].

Given its anti-inflammatory profile and metabolic benefits, the MD is increasingly recommended as a complementary strategy in the dietary management of HT, serving as a therapeutic counterpoint to the Western dietary pattern. Ruggeri et al. (2023) reported that high adherence to Mediterranean dietary principles was associated with significantly reduced antibody levels and improved patient-reported outcomes [88].

The Autoimmune Protocol (AIP) diet, which entails rigorous elimination of potential immunogenic foods followed by phased reintroduction, has been associated with reductions in high-sensitivity C-reactive protein and symptomatic improvement [89]. However, adherence may be limited by the restrictive nature of the diet, necessitating individualized dietary planning.

Iodine is vital for thyroid hormone synthesis, with dietary intake varying by region and cultural practices [90-91]. While iodine deficiency historically caused widespread hypothyroidism, iodization programs have reduced this issue but coincided with a rise in autoimmune thyroiditis (AIT) cases [92-93]. Excess iodine may enhance thyroglobulin immunogenicity, triggering immune responses marked by elevated TPOAb and TgAb, cytokine activation (e.g., IFN- γ), and increased IP-10 levels, all contributing to AIT development and severity [93]. Studies show that children with high urinary iodine often have higher TSH and lower thyroid hormone levels, with AIT diagnosed at a younger age [90,94]. Additionally, iodine exposure during delivery (e.g., povidone-iodine) may cause transient neonatal hypothyroidism, though typically resolving by age one [95].

Micronutrients such as selenium, vitamin D, zinc, and myo-inositol have been identified as modulators of thyroid autoimmunity [96-97]. Supplementation in deficient individuals

appears to attenuate antibody titers and improve thyroid function, although optimal dosing strategies remain under investigation.

Selenium is an essential micronutrient with antioxidant properties, vital for protecting the body against oxidative stress and preventing various diseases, including inflammatory, neurological, and cardiovascular disorders [98-99].

The thyroid gland contains one of the highest concentrations of selenium, which is crucial for the synthesis, activation, and metabolism of thyroid hormones [98]. Selenium also plays a significant role in immune system function, which is particularly relevant in autoimmune thyroiditis (AIT). Chronic selenium deficiency can predispose individuals to the development of AIT.

Selenium levels in the body are influenced by both the selenium content in the local soil and dietary intake. A study by Qian Wu et al. demonstrated that selenium deficiency is more common in regions with lower selenium intake, and the incidence of AIT is significantly higher in these areas compared to those with adequate selenium intake [100]. Another study further highlighted the role of selenium and selenoproteins in AIT pathogenesis, revealing that selenium levels were notably lower in AIT patients, while the level of selenoprotein H (SelH), which plays a role in thyroid hormone metabolism and oxidative stress response, was elevated [101]. This increased SelH level may reflect an enhanced antioxidant response to oxidative stress in AIT patients.

Increased oxidative stress and lower selenium levels were also observed in AIT patients in research conducted by Rahim Rostami et al., which suggested a link between selenium deficiency, elevated iodine levels, and the progression of thyroid dysfunction [102]. Selenium supplementation has shown promising effects on thyroid function in AIT patients by reducing thyroid autoantibodies (TPOAb, TgAb), lowering TSH, and improving antioxidant activity and regulatory T cell (Treg) levels, which could indicate a reduction in autoimmune activity [103-104]. Some studies have also suggested that selenium supplementation may restore euthyroidism in subclinical hypothyroid patients with AIT [105-106]

Vitamin D plays a crucial role in regulating the immune system, primarily by influencing the production of pro-inflammatory cytokines such as IL-1, IL-6, TNF- α , and IL-17 [107-108]. This regulatory effect of vitamin D has been implicated in various autoimmune diseases, including Hashimoto's Thyroiditis (HT) [109]. Vitamin D deficiency, particularly common in

regions with low sunlight, has been observed to exacerbate inflammatory processes and autoimmune conditions like HT, rheumatoid arthritis, and multiple sclerosis [110-111]. Several studies suggest that lower serum levels of vitamin D in HT patients correlate with higher titers of pro-inflammatory cytokines and may also impact cognitive function negatively. Specifically, lower vitamin D levels have been associated with poorer Montreal Cognitive Assessment (MoCA) scores in HT patients, which is particularly evident in children with severe hypothyroidism [112-114]. Despite these findings, the relationship between vitamin D deficiency and HT remains complex. While some studies confirm a clear correlation between low vitamin D levels and HT, others do not establish a definitive causality [115-120]. The influence of vitamin D on autoimmune thyroiditis (AIT) continues to be widely researched, with ongoing investigations into whether vitamin D deficiency acts as a risk factor for AIT or simply a consequence of the disease [121]. The need for vitamin D supplementation in individuals with autoimmune thyroid diseases, especially in those with a deficiency, is also emphasized to potentially mitigate inflammatory processes and improve patient outcomes [122].

4.2. Impact of Physical activity on the course of Hashimoto's Disease

Physical activity confers a range of immunomodulatory and metabolic benefits relevant to HT management. Regular moderate aerobic exercise has been shown to reduce proinflammatory cytokine levels, improve mood and energy levels, and enhance gut microbiota diversity. In a 2023 study by Kamińska et al. [123], implementation of the Mediterranean diet in conjunction with WHO-recommended levels of physical activity led to significant reductions in body fat and waist circumference among HT patients. The 10-week lifestyle intervention, including adherence to the Mediterranean diet and promotion of physical activity, demonstrated measurable improvements in body composition among women with Hashimoto's thyroiditis (HT), despite the absence of significant changes in body weight or reported physical activity levels at the group level.

While physical activity, assessed using MET-min/week, did not significantly change in the HT group (from 4549.5 ± 1592 to 4560.7 ± 2044 , $p = 0.878$), several significant changes in anthropometric parameters were observed. Notably, **BMI decreased significantly** from 24.7 ± 5.3 to 24.0 ± 4.7 kg/m² ($p < 0.05$), and **waist circumference was reduced** from 84.6 cm to 81.3 ± 14 cm ($p = 0.045$). In addition, **body fat percentage decreased significantly** from $30.1 \pm 9\%$ to $28.5 \pm 8.7\%$ ($p = 0.002$), while muscle mass remained unchanged.

Importantly, correlation analysis revealed that **increases in muscle mass and muscle glycogen content** were **strongly associated with changes in physical activity** ($\rho = 0.661$ and $\rho = 0.709$, respectively). Moreover, a nearly perfect correlation was observed between changes in **muscle mass and glycogen content** ($\rho = 0.947$), indicating coordinated physiological adaptation. Additionally, a higher baseline body weight was positively correlated with greater weight reduction over the course of the intervention ($\rho = 0.585$, $p = 0.028$).

These findings suggest that even in the absence of statistically significant changes in overall activity levels, **lifestyle interventions can lead to meaningful improvements in body composition** in women with HT. The results emphasize the importance of **qualitative changes in physical activity** and dietary adherence in modulating metabolic and inflammatory parameters in autoimmune thyroid disease [123].

Exercise may also ameliorate fatigue—a frequently reported symptom among HT patients—through its effects on mitochondrial function and central nervous system activation. Nonetheless, exercise regimens must be carefully tailored in cases of severe hypothyroidism to avoid exacerbation of symptoms.

4.3. Impact of Stress on the course of Hashimoto's Disease

Stress, both acute and chronic, is increasingly recognized as a potential environmental factor that may trigger autoimmune thyroiditis (AIT). Although research in this area remains limited, several studies suggest that stress disrupts immune system homeostasis, contributing to the development of autoimmune diseases. This disruption is thought to result from hormonal imbalances caused by the activation of the sympathetic-adrenal system and the hypothalamic-pituitary-adrenal (HPA) axis during stressful events. Such activation leads to the excessive release of catecholamines and the overproduction of glucocorticoids, including cortisol [124]. Chronic stress, in particular, has been linked to systemic inflammation, primarily through increased levels of pro-inflammatory cytokines, which may further influence the pathogenesis of AIT [124].

Moreover, stress appears to modulate thyroid function through its impact on thyroid-stimulating hormone (TSH). A study by Hua Hong and Jeonghun Lee explored the potential of TSH as a biomarker for stress, revealing that while TSH is typically regulated by free triiodothyronine (fT3) and free thyroxine (fT4) through a negative feedback loop, cortisol and

cytokine levels may also influence serum TSH concentrations. However, no significant correlation was found between TSH levels and stress questionnaires, suggesting the presence of confounding factors such as environmental influences, personality traits, or emotional regulation strategies [125].

Additionally, psychological stress has been shown to play a significant role in modulating autoimmune dynamics. The chronic stimulation of the HPA axis, which elevates cortisol and catecholamine levels, can influence cytokine profiles and immune cell trafficking [88]. Patients with Hashimoto's thyroiditis (HT) often report higher levels of perceived stress compared to healthy controls, and studies have demonstrated improvements in their condition following psychological interventions [126]. Psychological interventions such as mindfulness-based stress reduction (MBSR), cognitive-behavioral therapy (CBT), and yoga have shown promise in mitigating stress-related immunopathology [126]. Given the bidirectional relationship between thyroid dysfunction and mood disorders, psychological assessment and support should be considered a routine component of HT care.

In addition to these findings, one study revealed that AIT patients experienced higher levels of perceived stress compared to controls, despite having similar numbers of stressful life events. This study also demonstrated a correlation between the number of stressful life events and increased levels of anti-TPO antibodies, suggesting that stress may induce changes in immune pathways that contribute to the development of AIT [124]. These findings highlight the importance of addressing psychological stress as part of managing autoimmune thyroiditis, emphasizing the potential for therapeutic strategies to reduce stress and improve immune function in affected individuals.

5. Conclusions

The integration of lifestyle interventions into the clinical management of Hashimoto's thyroiditis represents a promising adjunct to pharmacotherapy. Evidence supports the efficacy of anti-inflammatory diets, structured physical activity, and stress-reduction techniques in modulating immunological markers and improving quality of life. Future research should prioritize longitudinal, controlled trials to delineate optimal intervention protocols and elucidate underlying mechanisms. In the interim, clinicians should consider adopting a personalized, interdisciplinary approach that empowers patients to engage in their own health optimization.

Authors' Contributions: Conceptualization was done by Alicja Podolska; methodology by Alicja Podolska and Agnieszka Woźniacka; software by Tomasz Pulanecki; checking by Barbara Boba; formal analysis by Julia Wątor; investigation by Jakub Krzeszowiak; resources by Aleksandra Ożga; data curation by Barbara Chojnacka; writing-rough preparation by Sylwia Bryksy; writing-review and editing by Patrycja Kolano; visualization by Alicja Podolska and Barbara Boba; supervision by Sylwia Bryksy; project administration by Tomasz Pulanecki; receiving funding by Alicja Podolska. All authors have read and agreed with the published version of the manuscript.

Funding statement: The study did not receive special funding.

Informed Consent Statement: Not applicable.

Acknowledgements: Not applicable.

Conflict of Interest Statement: The authors report that there are no conflict of interest.

References

1. Caturegli, P., De Remigis, A., & Rose, N. R. (2014). Hashimoto thyroiditis: Clinical and diagnostic criteria. *Autoimmunity Reviews*, 13, 391–397. <https://doi.org/10.1016/j.autrev.2014.01.007>
2. Hashimoto, H. (1912). Zur Kenntnis der lymphomatösen Veränderung der Schilddrüse (Struma lymphomatosa). *Archiv für Klinische Chirurgie*, 97, 219–248.
3. Pyzik, A., Grywalska, E., Matyjaszek-Matuszek, B., & Rolinski, J. (2015). Immune disorders in Hashimoto's thyroiditis: What do we know so far? *Journal of Immunology Research*, 2015, 979167. <https://doi.org/10.1155/2015/979167>
4. Ihnatowicz, P., Drywień, M., Wątor, P., & Wojsiat, J. (2020). The importance of nutritional factors and dietary management of Hashimoto's thyroiditis. *Annals of Agricultural and Environmental Medicine*, 27, 184–193. <https://doi.org/10.26444/aaem/112142>
5. American Thyroid Association. (n.d.). *Hashimoto's thyroiditis*. <https://www.thyroid.org/hashimotos-thyroiditis/>
6. TEMD Thyroid Study Group. (2023). *Diagnosis and treatment of thyroid disease guideline–2023* (pp. 5–7). Turkish Endocrinology and Metabolism Society.
7. Almahari, S. A., Maki, R., Al Teraifi, N., Alshaikh, S., Chandran, N., & Taha, H. (2023). Hashimoto thyroiditis beyond cytology: A correlation between cytological, hormonal,

- serological, and radiological findings. *Journal of Thyroid Research*, 2023, 5707120. <https://doi.org/10.1155/2023/5707120>
8. Klubo-Gwiedzinska, J., & Wartofsky, L. (2022). Hashimoto thyroiditis: An evidence-based guide to etiology, diagnosis and treatment. *Polish Archives of Internal Medicine*, 132, 16222. <https://doi.org/10.20452/pamw.16222>
 9. Wu, G., Zou, D., Cai, H., & Liu, Y. (2016). Ultrasonography in the diagnosis of Hashimoto's thyroiditis. *Frontiers in Bioscience*, 21(5), 1006–1012. <https://doi.org/10.2741/4437>
 10. Ralli, M., Angeletti, D., Fiore, M., et al. (2020). Hashimoto's thyroiditis: An update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. *Autoimmunity Reviews*, 19(10), 102649. <https://doi.org/10.1016/j.autrev.2020.102649>
 11. Weetman, A. P. (2021). An update on the pathogenesis of Hashimoto's thyroiditis. *Journal of Endocrinological Investigation*, 44(5), 883–890. <https://doi.org/10.1007/s40618-020-01387-2>
 12. Siegmann, E. M., Müller, H. H. O., Luecke, C., Philipsen, A., Kornhuber, J., & Grömer, T. W. (2018). Association of depression and anxiety disorders with autoimmune thyroiditis: A systematic review and meta-analysis. *JAMA Psychiatry*, 75, 577–584. <https://doi.org/10.1001/jamapsychiatry.2018.0190>
 13. Hu, X., Wang, X., Liang, Y., et al. (2022). Cancer risk in Hashimoto's thyroiditis: A systematic review and meta-analysis. *Frontiers in Endocrinology*, 13, 937871. <https://doi.org/10.3389/fendo.2022.937871>
 14. Caturegli, P., De Remigis, A., Chuang, K., et al. (2013). Hashimoto's thyroiditis: Celebrating the centennial through the lens of the Johns Hopkins Hospital surgical pathology records. *Thyroid*, 23, 142–150. <https://doi.org/10.1089/thy.2012.0317>
 15. McLeod, D. S., Caturegli, P., Cooper, D. S., et al. (2014). Variation in rates of autoimmune thyroid disease by race/ethnicity in US military personnel. *JAMA*, 311, 1563–1565. <https://doi.org/10.1001/jama.2014.1997>
 16. Song, R. H., Yao, Q. M., Wang, B., et al. (2019). Thyroid disorders in patients with myasthenia gravis: A systematic review and meta-analysis. *Autoimmunity Reviews*, 18, 102368. <https://doi.org/10.1016/j.autrev.2019.102368>
 17. Yao, Q., Song, Z., Wang, B., et al. (2019). Thyroid disorders in patients with systemic sclerosis: A systematic review and meta-analysis. *Autoimmunity Reviews*, 18, 634–636. <https://doi.org/10.1016/j.autrev.2018.12.006>

18. Nakamura, H., Usa, T., Motomura, M., et al. (2008). Prevalence of interrelated autoantibodies in thyroid diseases and autoimmune disorders. *Journal of Endocrinological Investigation*, 31, 861–865. <https://doi.org/10.1007/BF03349236>
19. Feldt-Rasmussen, U., Hoier-Madsen, M., Bech, K., et al. (1991). Anti-thyroid peroxidase antibodies in thyroid disorders and non-thyroid autoimmune diseases. *Autoimmunity*, 9, 245–254. <https://doi.org/10.3109/08916939109008086>
20. Bliddal, S., Nielsen, C. H., & Feldt-Rasmussen, U. (2017). Recent advances in understanding autoimmune thyroid disease: The tallest tree in the forest of polyautoimmunity. *F1000Research*, 6, 1776. <https://doi.org/10.12688/f1000research.12084.1>
21. Lazúrová, I., & Benhatchi, K. (2012). Autoimmune thyroid diseases and nonorgan-specific autoimmunity. *Polish Archives of Internal Medicine*, 122(Suppl 1), 55–59.
22. Zeber-Lubecka, N., & Hennig, E. E. (2021). Genetic susceptibility to joint occurrence of polycystic ovary syndrome and Hashimoto's thyroiditis: How far is our understanding? *Frontiers in Immunology*, 12, 606620. <https://doi.org/10.3389/fimmu.2021.606620>
23. Hu, X., Chen, Y., Shen, Y., et al. (2022). Correlation between Hashimoto's thyroiditis and polycystic ovary syndrome: A systematic review and meta-analysis. *Frontiers in Endocrinology*, 13, 1025267. <https://doi.org/10.3389/fendo.2022.1025267>
24. Dong, Y. H., & Fu, D. G. (2014). Autoimmune thyroid disease: Mechanism, genetics and current knowledge. *European Review for Medical and Pharmacological Sciences*, 18, 3611–3618.
25. Kyritsi, E. M., & Kanaka-Gantenbein, C. (2020). Autoimmune thyroid disease in specific genetic syndromes in childhood and adolescence. *Frontiers in Endocrinology*, 11, 543. <https://doi.org/10.3389/fendo.2020.00543>
26. Brix, T. H., & Hegedüs, L. (2012). Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. *Clinical Endocrinology*, 76, 457–464. <https://doi.org/10.1111/j.1365-2265.2011.04284.x>
27. Brand, O., Gough, S., & Heward, J. (2005). HLA, CTLA-4 and PTPN22: The shared genetic master key to autoimmunity? *Expert Reviews in Molecular Medicine*, 7, 1–15. <https://doi.org/10.1017/S1462399405009194>
28. Weetman, A. P. (2013). The immunopathogenesis of chronic autoimmune thyroiditis one century after Hashimoto. *European Thyroid Journal*, 1, 243–250. <https://doi.org/10.1159/000356528>

29. Johar, A., Sarmiento Monroy, J. C., Rojas Villarraga, A., et al. (2016). Definition of mutations in polyautoimmunity. *Journal of Autoimmunity*, 72, 65–72. <https://doi.org/10.1016/j.jaut.2016.05.003>
30. Santos, L. R., Duraes, C., Mendes, A., et al. (2014). A polymorphism in the promoter region of the selenoprotein S gene (SEPS1) contributes to Hashimoto's thyroiditis susceptibility. *Journal of Clinical Endocrinology and Metabolism*, 99, E719–E723. <https://doi.org/10.1210/jc.2013-3379>
31. Jia, X., Wang, B., Yao, Q., et al. (2018). Variations in CD14 gene are associated with autoimmune thyroid diseases in the Chinese population. *Frontiers in Endocrinology*, 9, 811. <https://doi.org/10.3389/fendo.2018.00811>
32. Lepez, T., Vandewoestyne, M., & Deforce, D. (2013). Fetal microchimeric cells in autoimmune thyroid diseases: Harmful, beneficial or innocent for the thyroid gland? *Chimerism*, 4, 111–118. (DOI not found)
33. Mynster Kronborg, T., Frohnert Hansen, J., Nielsen, C. H., et al. (2016). Effects of the commercial flame retardant mixture DE 71 on cytokine production by human immune cells. *PLoS One*, 11, e0154621. <https://doi.org/10.1371/journal.pone.0154621>
34. Wiersinga, W. M. (2016). Clinical relevance of environmental factors in the pathogenesis of autoimmune thyroid disease. *Endocrinology and Metabolism (Seoul)*, 31, 213–222. <https://doi.org/10.3803/EnM.2016.31.2.213>
35. Gong, B., Wang, C., Meng, F., et al. (2021). Association between gut microbiota and autoimmune thyroid disease: A systematic review and meta-analysis. *Frontiers in Endocrinology*, 12, 774362. <https://doi.org/10.3389/fendo.2021.774362>
36. Aghini Lombardi, F., Fiore, E., Tonacchera, M., et al. (2013). The effect of voluntary iodine prophylaxis in a small rural community: The Pescopagano survey 15 years later. *Journal of Clinical Endocrinology and Metabolism*, 98, 1031–1039. <https://doi.org/10.1210/jc.2012-3300>
37. Carayanniotis, G. (2007). Recognition of thyroglobulin by T cells: The role of iodine. *Thyroid*, 17, 963–973. <https://doi.org/10.1089/thy.2007.0028>
38. Alexander, E. K., Pearce, E. N., Brent, G. A., et al. (2017). 2017 Guidelines of the American Thyroid Association for the diagnosis and management of thyroid disease during pregnancy and the postpartum. *Thyroid*, 27, 315–389. <https://doi.org/10.1089/thy.2016.0457>
39. Toulis, K. A., Anastasilakis, A. D., Tzellos, T. G., et al. (2010). Selenium supplementation in the treatment of Hashimoto's thyroiditis: A systematic review and a meta-analysis. *Thyroid*, 20, 1163–1173. <https://doi.org/10.1089/thy.2010.0107>
40. Winther, K. H., Wichman, J. E., Bonnema, S. J., et al. (2017). Insufficient documentation for clinical efficacy of selenium supplementation in chronic autoimmune thyroiditis, based on a systematic review and meta-analysis. *Endocrine*, 55, 376–385. <https://doi.org/10.1007/s12020-016-1138-0>

41. Metso, S., Hyytiä-Ilmonen, H., Kaukinen, K., et al. (2012). Gluten-free diet and autoimmune thyroiditis in patients with celiac disease: A prospective controlled study. *Scandinavian Journal of Gastroenterology*, 47, 43–48. <https://doi.org/10.3109/00365521.2011.619253>
42. Krysiak, R., Szkróbka, W., & Okopień, B. (2019). The effect of gluten-free diet on thyroid autoimmunity in drug-naive women with Hashimoto's thyroiditis: A pilot study. *Experimental and Clinical Endocrinology & Diabetes*, 127, 417–422. <https://doi.org/10.1055/a-0905-7141>
43. Giordano, C., Stassi, G., De Maria, R., et al. (1997). Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. *Science*, 275, 960–963. <https://doi.org/10.1126/science.275.5304.960>
44. Ahmed, R., Al Shaikh, S., & Akhtar, M. (2012). Hashimoto thyroiditis: A century later. *Advances in Anatomic Pathology*, 19, 181–186. <https://doi.org/10.1097/PAP.0b013e31825d3fc4>
45. Hennessey, J. V. (2011). Clinical review: Riedel's thyroiditis: A clinical review. *Journal of Clinical Endocrinology and Metabolism*, 96, 3031–3041. <https://doi.org/10.1210/jc.2011-1093>
46. Stone, J. H., Khosroshahi, A., Deshpande, V., et al. (2012). Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations. *Arthritis & Rheumatism*, 64, 3061–3067. <https://doi.org/10.1002/art.34684>
47. Zhang, Q. Y., Ye, X. P., Zhou, Z., et al. (2022). Lymphocyte infiltration and thyrocyte destruction are driven by stromal and immune cell components in Hashimoto's thyroiditis. *Nature Communications*, 13, 775. <https://doi.org/10.1038/s41467-022-28219-2>
48. Pedersen, I. B., Knudsen, N., Jorgensen, T., et al. (2003). Thyroid peroxidase and thyroglobulin autoantibodies in a large survey of populations with mild and moderate iodine deficiency. *Clinical Endocrinology*, 58, 36–42. <https://doi.org/10.1046/j.1365-2265.2003.01708.x>
49. Procaccini, C., Carbone, F., Galgani, M., et al. (2011). Obesity and susceptibility to autoimmune diseases. *Expert Review of Clinical Immunology*, 7, 287–294. <https://doi.org/10.1586/eci.11.21>
50. Manzel, A., Muller, D. N., Hafler, D. A., et al. (2014). Role of “Western diet” in inflammatory autoimmune diseases. *Current Allergy and Asthma Reports*, 14, 404. <https://doi.org/10.1007/s11882-014-0404-6>
51. de Castro, M. M., Pascoal, L. B., Steigleder, K. M., et al. (2021). Role of diet and nutrition in inflammatory bowel disease. *World Journal of Experimental Medicine*, 11, 1–16. <https://doi.org/10.5493/wjem.v11.i1.1>
52. Philippou, E., & Nikiphorou, E. (2018). Are we really what we eat? Nutrition and its role in the onset of rheumatoid arthritis. *Autoimmunity Reviews*, 17, 1074–1077. <https://doi.org/10.1016/j.autrev.2018.06.012>
53. Alwarith, J., Kahleova, H., Rembert, E., et al. (2019). Nutrition interventions in rheumatoid arthritis: The potential use of plant-based diets. A review. *Frontiers in Nutrition*, 6, 141. <https://doi.org/10.3389/fnut.2019.00141>

54. Gioia, C., Lucchino, B., Tarsitano, M. G., et al. (2020). Dietary habits and nutrition in rheumatoid arthritis: Can diet influence disease development and clinical manifestations? *Nutrients*, *12*, 1456. <https://doi.org/10.3390/nu12051456>
55. Ricketts, J. R., Rothe, M. J., & Grant-Kels, J. M. (2010). Nutrition and psoriasis. *Clinical Dermatology*, *28*(6), 615–626. <https://doi.org/10.1016/j.clindermatol.2010.04.001>
56. Christ, A., Lauterbach, M., & Latz, E. (2019). Western diet and the immune system: An inflammatory connection. *Immunity*, *51*(5), 794–811. <https://doi.org/10.1016/j.immuni.2019.09.020>
57. Mahmoudi, M., & Rezaei, N. (Eds.). (2019). *Nutrition and immunity*. Springer Nature. <https://doi.org/10.1007/978-3-030-15187-6>
58. McCord, J. M. (1993). Human disease, free radicals, and the oxidant/antioxidant balance. *Clinical Biochemistry*, *26*(5), 351–357. [https://doi.org/10.1016/0009-9120\(93\)90085-O](https://doi.org/10.1016/0009-9120(93)90085-O)
59. Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T., Mazur, M., & Telser, J. (2007). Free radicals and antioxidants in normal physiological functions and human disease. *International Journal of Biochemistry & Cell Biology*, *39*(1), 44–84. <https://doi.org/10.1016/j.biocel.2006.07.001>
60. Ruggeri, R. M., Vicchio, T. M., Cristani, M., et al. (2016). Oxidative stress and advanced glycation end products in Hashimoto's thyroiditis. *Thyroid*, *26*(4), 504–511. <https://doi.org/10.1089/thy.2015.0436>
61. Ruggeri, R. M., Cristani, M. T., Crupi, F. S., et al. (2022). Evaluation of paraoxonase activity and association with serum advanced glycation end products as reliable markers of oxidative stress in Hashimoto's thyroiditis. *Minerva Endocrinologica*. <https://doi.org/10.23736/S0391-1977.22.04702-8>
62. Brady, D. M. (2012). Autoimmune disease: A modern epidemic? Molecular mimicry, the hygiene hypothesis, stealth infections, and other examples of disconnect between medical research and the practice of clinical medicine. *Townsend Letter*, (347), 45–50.
63. Merra, G., Noce, A., Marrone, G., et al. (2021). Influence of Mediterranean diet on human gut microbiota. *Nutrients*, *13*(7), 2279. <https://doi.org/10.3390/nu13072279>
64. Requena, T., Martínez-Cuesta, M. C., & Peláez, C. (2018). Diet and microbiota linked in health and disease. *Food Function*, *9*(2), 688–704. <https://doi.org/10.1039/C7FO01599A>
65. Rinninella, E., Cintoni, M., Raoul, P., et al. (2019). Food components and dietary habits: Keys for a healthy gut microbiota composition. *Nutrients*, *11*(10), 2393. <https://doi.org/10.3390/nu11102393>
66. Barrea, L., Muscogiuri, G., Frias-Toral, E., et al. (2021). Nutrition and immune system: From the Mediterranean diet to dietary supplements through the microbiota. *Critical Reviews in Food Science and Nutrition*, *61*(18), 3066–3090. <https://doi.org/10.1080/10408398.2020.1724137>
67. Lerner, A., & Matthias, T. (2015). Changes in intestinal tight junction permeability associated with industrial food additives explain the rising incidence of autoimmune disease. *Autoimmunity Reviews*, *14*(6), 479–489. <https://doi.org/10.1016/j.autrev.2015.01.003>

68. Ruggeri, R. M., Giovino, S., Barbalace, M. C., et al. (2021). Influence of dietary habits on oxidative stress markers in Hashimoto's thyroiditis. *Thyroid*, 31(1), 96–105. <https://doi.org/10.1089/thy.2020.0223>
69. Keys, A., Menotti, A., Aravanis, C., et al. (1984). The seven countries study: 2289 deaths in 15 years. *Preventive Medicine*, 13(2), 141–154. [https://doi.org/10.1016/0091-7435\(84\)90004-7](https://doi.org/10.1016/0091-7435(84)90004-7)
70. Angeloni, C., Malaguti, M., Barbalace, M. C., & Hrelia, S. (2017). Bioactivity of olive oil phenols in neuroprotection. *International Journal of Molecular Sciences*, 18(11), 2230. <https://doi.org/10.3390/ijms18112230>
71. Schwingshackl, L., Morze, J., & Hoffmann, G. (2020). Mediterranean diet and health status: Active ingredients and pharmacological mechanisms. *British Journal of Pharmacology*, 177(6), 1241–1257. <https://doi.org/10.1111/bph.14948>
72. Kapoor, B., Kapoor, D., Gautam, S., et al. (2021). Dietary polyunsaturated fatty acids (PUFAs): Uses and potential health benefits. *Current Nutrition Reports*, 10(3), 232–242. <https://doi.org/10.1007/s13668-021-00352-5>
73. Calder, P. C. (2017). Omega-3 fatty acids and inflammatory processes: From molecules to man. *Biochemical Society Transactions*, 45(5), 1105–1115. <https://doi.org/10.1042/BST20160474>
74. Jacobs, D. R., Gross, M. D., & Tapsell, L. C. (2009). Food synergy: An operational concept for understanding nutrition. *The American Journal of Clinical Nutrition*, 89(5), 1543S–1548S. <https://doi.org/10.3945/ajcn.2009.26736Q>
75. Hrelia, S., Barbalace, M. C., Cannavò, S., & Ruggeri, R. M. (2023). Commentary: Fish and the thyroid: A Janus Bifrons relationship caused by pollutants and the omega-3 polyunsaturated fatty acids. *Frontiers in Endocrinology*, 14, 1138245. <https://doi.org/10.3389/fendo.2023.1138245>
76. Di Daniele, N., Noce, A., Vidiri, M. F., et al. (2017). Impact of Mediterranean diet on metabolic syndrome, cancer and longevity. *Oncotarget*, 8(47), 8947–8979. <https://doi.org/10.18632/oncotarget.13557>
77. Kesse-Guyot, E., Ahluwalia, N., Lassale, C., et al. (2013). Adherence to Mediterranean diet reduces the risk of metabolic syndrome: A 6-year prospective study. *Nutrition, Metabolism and Cardiovascular Diseases*, 23(7), 677–683. <https://doi.org/10.1016/j.numecd.2012.03.001>
78. Salas-Salvadó, J., Fernández-Ballart, J., Ros, E., et al. (2008). Effect of a Mediterranean diet supplemented with nuts on metabolic syndrome status: One-year results of the PREDIMED randomized trial. *Archives of Internal Medicine*, 168(22), 2449–2458. <https://doi.org/10.1001/archinte.168.22.2449>
79. Romaguera, D., Guevara, M., Norat, T., et al. (2011). Mediterranean diet and type 2 diabetes risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study: The InterAct project. *Diabetes Care*, 34(8), 1913–1918. <https://doi.org/10.2337/dc11-0294>

80. Salas-Salvadó, J., Bulló, M., Babio, N., et al. (2011). Reduction in the incidence of type 2 diabetes with the Mediterranean diet: Results of the PREDIMED-Reus nutrition intervention randomized trial. *Diabetes Care*, 34(1), 14–19. <https://doi.org/10.2337/dc10-1839>
81. Laudisio, D., Barrea, L., Muscogiuri, G., et al. (2020). Breast cancer prevention in premenopausal women: Role of the Mediterranean diet and its components. *Nutrition Research Reviews*, 33(1), 19–32. <https://doi.org/10.1017/S0954422419000171>
82. Maruca, A., Catalano, R., Bagetta, D., et al. (2019). The Mediterranean diet as source of bioactive compounds with multi-targeting anti-cancer profile. *European Journal of Medicinal Chemistry*, 181, 111579. <https://doi.org/10.1016/j.ejmech.2019.06.061>
83. de la Rubia Ortí, J. E., García-Pardo, M. P., Drehmer, E., et al. (2018). Improvement of main cognitive functions in patients with Alzheimer's disease after treatment with coconut oil enriched Mediterranean diet: A pilot study. *Journal of Alzheimer's Disease*, 65, 577–587. <https://doi.org/10.3233/JAD-180266>
84. Gardener, H., & Caunca, M. R. (2018). Mediterranean diet in preventing neurodegenerative diseases. *Current Nutrition Reports*, 7, 10–20. <https://doi.org/10.1007/s13668-018-0226-1>
85. Santangelo, C., Vari, R., Scazzocchio, B., et al. (2018). Anti-inflammatory activity of extra virgin olive oil polyphenols: Which role in the prevention and treatment of immune-mediated inflammatory diseases? *Endocrine, Metabolic & Immune Disorders Drug Targets*, 18, 36–50. <https://doi.org/10.2174/1871530317666170215120422>
86. Li, X., Bi, X., Wang, S., et al. (2019). Therapeutic potential of ω -3 polyunsaturated fatty acids in human autoimmune diseases. *Frontiers in Immunology*, 10, 2241. <https://doi.org/10.3389/fimmu.2019.02241>
87. UNESCO. (n.d.). Mediterranean Diet. Retrieved from <https://ich.unesco.org/en/RL/mediterranean-diet-00884>
88. Ruggeri, R. M., Barbalace, M. C., Croce, L., Malaguti, M., Campennì, A., Rotondi, M., et al. (2023). Autoimmune thyroid disorders: The Mediterranean diet as a protective choice. *Nutrients*, 15(18), 3953. <https://doi.org/10.3390/nu15183953>
89. Abbott, R. D., Hashimoto, M., Kaname, T., et al. (2019). The autoimmune protocol diet modifies clinical and serologic features in Hashimoto's thyroiditis: A 10-week pilot study. *Cureus*, 11(10), e4556. <https://doi.org/10.7759/cureus.4556>
90. Lee, Y. J., Cho, S. W., Lim, Y. H., Kim, B. N., Kim, J. I., Hong, Y. C., Park, Y. J., Shin, C. H., & Lee, Y. A. (2023). Relationship of iodine excess with thyroid function in 6-year-old children living in an iodine-replete area. *Frontiers in Endocrinology*, 14, 1099824. <https://doi.org/10.3389/fendo.2023.1099824>
91. Lisco, G., De Tullio, A., Triggiani, D., Zupo, R., Giagulli, V. A., De Pergola, G., et al. (2023). Iodine deficiency and iodine prophylaxis: An overview and update. *Nutrients*, 15, 1004. <https://doi.org/10.3390/nu15041004>

92. Yu, Z., Yu, Y., Wan, Y., Fan, J., Meng, H., Li, S., et al. (2021). Iodine intake level and incidence of thyroid disease in adults in Shaanxi province: A cross-sectional study. *Annals of Translational Medicine*, 9, 1567. <https://doi.org/10.21037/atm-21-3373>
93. Duntas, L. H. (2015). The role of iodine and selenium in autoimmune thyroiditis. *Hormone and Metabolic Research*, 47, 721–726. <https://doi.org/10.1055/s-0035-1554713>
94. Palaniappan, S., Shanmughavelu, L., Prasad, H. K., Subramaniam, S., Krishnamoorthy, N., & Lakkappa, L. (2017). Improving iodine nutritional status and increasing prevalence of autoimmune thyroiditis in children. *Indian Journal of Endocrinology and Metabolism*, 21, 85–89. <https://doi.org/10.4103/2230-8210.196026>
95. Yokomichi, H., Mochizuki, M., Kojima, R., Horiuchi, S., Ooka, T., Akiyama, Y., et al. (2022). Mother's iodine exposure and infants' hypothyroidism: The Japan Environment and Children's Study (JECS). *Endocrine Journal*, 69, 9–21. <https://doi.org/10.1507/endocrj.EJ21-0462>
96. Danailova, Y., Velikova, T., Nikolaev, G., et al. (2022). Nutritional management of thyroiditis of Hashimoto. *International Journal of Molecular Sciences*, 23, 5144. <https://doi.org/10.3390/ijms23095144>
97. Ruggeri, R. M., Giovinazzo, S., Barbalace, M. C., Cristani, M., Alibrandi, A., Vicchio, T. M., et al. (2020). Influence of dietary habits on oxidative stress markers in Hashimoto's thyroiditis. *Thyroid*. <https://doi.org/10.1089/thy.2020.0299>
98. Lacka, K., & Szeliga, A. (2015). Significance of selenium in thyroid physiology and pathology. *Polski Merkuriusz Lekarski*, 38, 348–353.
99. Szeliga, A., Czyżyk, A., Niedzielski, P., Mleczek, M., Maciejewski, A., Dorszewska, J., et al. (2018). Assessment of serum selenium concentration in patients with autoimmune thyroiditis in Poznań district. *Polski Merkuriusz Lekarski*, 45, 150–153.
100. Wu, Q., Wang, Y., Chen, P., Wei, J., Lv, H., Wang, S., et al. (2022). Increased incidence of Hashimoto thyroiditis in selenium deficiency: A prospective 6-year cohort study. *Journal of Clinical Endocrinology & Metabolism*, 107(11), e3603–e3611. <https://doi.org/10.1210/clinem/dgac496>
101. Cinemre, D. A., Cinemre, G. C., Serinkan, F. B., Degirmencioglu, S., Bahtiyar, N., & Aydemir, B. (2022). The role of selenium, selenoproteins and oxidative DNA damage in etio-pathogenesis of Hashimoto thyroiditis. *Journal of Elementology*, 27(3), 755–764. <https://doi.org/10.5601/jelem.2022.27.3.2507>
102. Rostami, R., Nourooz-Zadeh, S., Mohammadi, A., Khalkhali, H. R., Ferns, G., & Nourooz-Zadeh, J. (2020). Serum selenium status and its interrelationship with serum biomarkers of thyroid function and antioxidant defense in Hashimoto's thyroiditis. *Antioxidants*, 9(11), 1070. <https://doi.org/10.3390/antiox9111070>

103. Hu, Y., Feng, W., Chen, H., Shi, H., Jiang, L., Zheng, X., et al. (2021). Effect of selenium on thyroid autoimmunity and regulatory T cells in patients with Hashimoto's thyroiditis: A prospective randomized-controlled trial. *Clinical and Translational Science*, 14(4), 1390–1402. <https://doi.org/10.1111/cts.13078>
104. Wang, L. F., Sun, R. X., Li, C. F., & Wang, X. H. (2021). The effects of selenium supplementation on antibody titres in patients with Hashimoto's thyroiditis. *Endokrynologia Polska*, 72(6), 666–667. <https://doi.org/10.5603/EP.a2021.0076>
105. Pirola, I., Gandossi, E., Agosti, B., Delbarba, A., & Cappelli, C. (2016). Selenium supplementation could restore euthyroidism in subclinical hypothyroid patients with autoimmune thyroiditis. *Endokrynologia Polska*, 67(6), 567–571.
106. Manevska, N., Stojanoski, S., & Makazlieva, T. (2019). Selenium treatment effect in auto-immune Hashimoto thyroiditis in Macedonian population. *Journal of Endocrinology and Metabolism*, 9(1), 22–28.
107. Kalicanin, D., Cvek, M., Baric, A., Skrabic, V., Punda, A., & Boraska Perica, V. (2023). Associations between vitamin D levels and dietary patterns in patients with Hashimoto's thyroiditis. *Frontiers in Nutrition*, 10, 1188612. <https://doi.org/10.3389/fnut.2023.1188612>
108. Czarnywojtek, A., Florek, E., Pietrńczyk, K., Sawicka-Gutaj, N., Ruchała, M., Ronen, O., et al. (2023). The role of vitamin D in autoimmune thyroid diseases: A narrative review. *Journal of Clinical Medicine*, 12(5), 1452. <https://doi.org/10.3390/jcm12051452>
109. Siddiq, A., Naveed, A. K., Ghaffar, N., Aamir, M., & Ahmed, N. (2023). Association of pro-inflammatory cytokines with vitamin D in Hashimoto's thyroid autoimmune disease. *Medicina (Kaunas)*, 59(5), 853. <https://doi.org/10.3390/medicina59050853>
110. Maciejewski, A., Kowalczyk, M. J., Herman, W., Czyżyk, A., Kowalska, M., Żaba, R., et al. (2019). Vitamin D receptor gene polymorphisms and autoimmune thyroiditis: Are they associated with disease occurrence and its features? *BioMed Research International*, 2019, 8197580. <https://doi.org/10.1155/2019/8197580>
111. Chao, G., Zhu, Y., & Fang, L. (2020). Correlation between Hashimoto's thyroiditis-related thyroid hormone levels and 25-hydroxyvitamin D. *Frontiers in Endocrinology (Lausanne)*, 11, 4. <https://doi.org/10.3389/fendo.2020.00004>
112. Xu, J., Zhu, X. Y., Sun, H., Xu, X. Q., Xu, S. A., Suo, Y., et al. (2018). Low vitamin D levels are associated with cognitive impairment in patients with Hashimoto thyroiditis. *BMC Endocrine Disorders*, 18, 87. <https://doi.org/10.1186/s12902-018-0281-z>
113. Kim, D. (2016). Low vitamin D status is associated with hypothyroid Hashimoto's thyroiditis. *Hormones (Athens)*, 15(3), 385–393. <https://doi.org/10.14310/horm.2002.1612>
114. Gierach, M., & Junik, R. (2023). The role of vitamin D in women with Hashimoto's thyroiditis. *Endokrynologia Polska*, 74(2), 176–180. <https://doi.org/10.5603/EP.a2022.0122>

115. Rola, R., Trusewicz, E., Bieńkowski, T., & Studzińska, S. (2021). Application of dried blood spots and serum samples for the determination of vitamin D metabolites in the group of healthy women and with Hashimoto's thyroiditis. *Chromatographia*, 84, 695–701. <https://doi.org/10.1007/s10337-021-04092-3>
116. Anaraki, P. V., Aminorroaya, A., Amini, M., Momeni, F., Feizi, A., Iraj, B., et al. (2017). Effect of vitamin D deficiency treatment on thyroid function and autoimmunity markers in Hashimoto's thyroiditis: A double-blind randomized placebo-controlled clinical trial. *Journal of Research in Medical Sciences*, 22, 103.
117. Yavuzer, H., Işık, S., Cengiz, M., Bolayırılı, İ. M., Döventaş, A., & Erdinçler, D. S. (2017). The relationship between vitamin D levels and receptor activator of nuclear factor ligand in Hashimoto's thyroiditis. *Medical Bulletin of Haseki*, 55(3), 261–268.
118. Cvek, M., Kalicanin, D., Baric, A., Vuletic, M., Gunjaca, I., Lovric, V. T., et al. (2021). Vitamin D and Hashimoto's thyroiditis: Observations from CROHT Biobank. *Nutrients*, 13(8), 2793. <https://doi.org/10.3390/nu13082793>
119. Botelho, I. M. B., Neto, A. M., Silva, C. A., Tambascia, M. A., Alegre, S. M., & Zantut-Wittmann, D. E. (2018). Vitamin D in Hashimoto's thyroiditis and its relationship with thyroid function and inflammatory status. *Endocrine Journal*, 65(10), 1029–1037. <https://doi.org/10.1507/endocrj.EJ18-0217>
120. Filipova, L., Lazurova, Z., Fulop, P., & Lazurova, I. (2023). Vitamin D insufficiency is not associated with thyroid autoimmunity in Slovak women with Hashimoto's disease. *Bratislavské lekárske listy*, 124(3), 182–186.
121. Maciejewski, A., Wójcicka, M., Roszak, M., Losy, J., & Łacka, K. (2015). Assessment of vitamin D level in autoimmune thyroiditis patients and a control group in the Polish population. *Advances in Clinical and Experimental Medicine*, 24(5), 801–806. <https://doi.org/10.17219/acem/32677>
122. Gasic, S., Smiljic, S., Milanovic, Z., Gasic, M., Ilic, S., & Bogosavljevic, I., et al. (2023). Relationship between low vitamin D levels with Hashimoto thyroiditis. *Srp Arh Celok Lek*, 151(5–6), 296–301.
123. Kamińska, W., Wiśniewska, K., & Okręglińska, K., et al. (2023). Lifestyle intervention towards Mediterranean diet, physical activity adherence and anthropometric parameters in women with Hashimoto's thyroiditis. *Annals of Agricultural and Environmental Medicine*, 30(1), 111–117. <https://doi.org/10.26444/aaem/162393>
124. Vaivode, I., Zake, T., Strele, I., et al. (2023). Stress-related immune response and selenium status in autoimmune thyroid disease patients. *International Journal of Molecular Sciences*, 24(3), 2440. <https://doi.org/10.3390/ijms24032440>

125. Hong, H., & Lee, J. (2022). Thyroid-stimulating hormone as a biomarker for stress after thyroid surgery: A prospective cohort study. *Medical Science Monitor*, 28, e937957. <https://doi.org/10.12659/MSM.937957>
126. Cyna, W., Wojciechowska, A., Szybiak-Skora, W., & Lacka, K. (2024). The impact of environmental factors on the development of autoimmune thyroiditis—Review. *Biomedicines*, 12(8), 1788. <https://doi.org/10.3390/biomedicines12081788>